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Safety of gadolinium contrast angiography in
patients with chronic renal insufficiency
Albert D. Sam II, MD,a Mark D. Morasch, MD,a Jeremy Collins, MD,b Gina Song, MD,b Richard Chen,
MD,b and F. Scott Pereles, MD,b Chicago, Ill
Objective: To prevent iodinated contrast medium–induced nephrotoxicity, gadolinium has been used increasingly for
magnetic resonance angiography (MRA) or conventional digital subtraction angiography (DSA) to visualize arterial
anatomy in patients undergoing vascular surgery who are considered at high risk because of chronic renal insufficiency.
We assessed the safety of gadolinium-based contrast medium as a substitute for iodinated contrast medium–enhanced
examinations. We determined the incidence of gadolinium-induced nephrotoxicity in a clinical setting and searched for
contributing risk factors.
Patients and Methods: In a single-center retrospective study from December 1999 to January 2001, 218 inpatients
underwent MRA and 42 inpatients underwent DSA, with gadolinium as the sole contrast agent. Patient comorbid
conditions, indications for vascular imaging, contrast dose, urine output, baseline and post-procedure serum creatinine
concentration (SCr), and outcome were recorded for all patients in whom gadolinium-induced renal failure developed.
Results: Of 260 patients who received gadolinium-based contrast agents, at a dose of 0.25 mmol/kg or more, 195
patients (75%) had pre-test baseline chronic renal insufficiency. In 7 of 195 patients (3.5%) acute renal failure developed
after gadolinium-based contrast medium administration, for MRA (n  153) in 3 patients (1.9%) and DSA (n  42) in
4 patients (9.5%). Average baseline SCr in the 195 patients with chronic renal insufficiency was 38.2 1.6 mL/min/1.73
m2, and in the 7 patients in whom acute renal failure developed, baseline SCr was 32.5 7.8 mL/min/1.73 m2 (P .33).
Respective intravenous and intra-arterial gadolinium doses in these 7 patients ranged from 0.31 to 0.41 mmol/kg for
MRA and 0.27 to 0.42 mmol/kg for DSA. Acute renal failure did not develop in any of 65 patients with normal baseline
SCr.
Conclusion: Despite reports of negligible nephrotoxicity, rarely gadolinium-based contrast agents can cause acute renal
failure in patients with underlying chronic renal insufficiency. Estimation of creatinine clearance alone does not enable
prediction of which patients are likely to have acute renal failure. Patients at high-risk should be identified, and
prophylactic measures should be taken to reduce the risk for nephrotoxicity. (J Vasc Surg 2003;38:313-8.)
Specific comorbid conditions such as chronic renal
insufficiency are important to consider when contemplat-
ing angiography to evaluate vascular lesions. Iodinated
contrast agents used during radiographic evaluation of the
vascular tree are nephrotoxic, and not uncommonly they
can induce renal failure. Gadolinium-based contrast formu-
lations are noniodinated contrast agents that are predomi-
nately infused intravenously during vascular imaging with
magnetic resonance angiography (MRA). Intravenous ga-
dolinium-based contrast medium is safe and well-tolerated,
with no nephrotoxicity when given within recommended
dosages.1-3 Prospective studies have evaluated the safety of
gadolinium, but have been criticized because of relatively
small sample sizes.4 Patients in several of these studies
received a much lower dose of gadolinium (0.1 mmol/kg)
than is commonly infused during routine clinical MRA.
Gadolinium is also used as an intra-arterial alternative to
iodinated contrast agents during catheter-based digital
subtraction angiography (DSA). This off-label usage is
generally considered safe despite a paucity of strong evi-
dence.
Two recent reports of renal failure after intra-arterial
infusion of gadolinium have led to new questions regarding
its clinical safety.5,6 We undertook this investigation in an
attempt to identify the incidence of gadolinium-induced
nephropathy, and we sought to identify risk factors that
may predispose to this complication.
METHODS
Records for all 260 inpatients who received high-dose
intravenous or intra-arterial gadolinium (0.25 mmol/kg or
greater) at Northwestern Memorial Hospital from Decem-
ber 1999 to January 2001 were reviewed retrospectively
according to guidelines indicated by the Northwestern
UniversityMedical School Institutional Review Board. The
average age of the study population was 62 years (range,
20-92 years). During that 24-month period 218 inpatient
gadolinium-enhanced peripheral MRA examinations (non-
cardiac thoracic, mesentero-renal, and lower extremity)
were performed. During that same time period 42 inpa-
tients underwent DSA in the interventional radiology suite
or in the operating room, with gadolinium as the sole
intra-arterial contrast agent. Charts for all 260 inpatients
were reviewed, and baseline renal function was calculated.
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Patients who had acute renal failure within 48 hours of
administration of the agent were identified and their charts
reviewed in further detail. Patient history, hospital admis-
sion status, concomitant medications, comorbid condi-
tions, indication for vascular imaging, urine output, and
baseline pre-test and daily inpatient laboratory values were
recorded from the medical records of patients in whom
renal failure developed. Chronic renal insufficiency was
defined as creatinine clearance less than 80 mL/min/1.73
m2. Serum creatinine concentration (SCr) was recorded as
milligrams per deciliter, and creatinine clearance was calcu-
lated according to the formula (140 age 72 SCr)
weight in kilograms (multiplied by 0.85 for female pa-
tients). Acute renal failure was defined as an increase in SCr
greater than 1.0 mg/dL within 48 hours of gadolinium
infusion7 and concomitant oliguria (urine output0.1-0.5
mL/kg/h) or anuria (urine output 0.1 mL/kg/h).
RESULTS
Of 260 patients, 195 (75%) had chronic renal insuffi-
ciency, defined as baseline creatinine clearance less than 80
mL/min/1.73 m2. Of 218 patients who underwent MRA,
153 patients (70%) had baseline chronic renal insufficiency
(average pre-test SCr, 2.1 mg/dL; average creatinine
clearance, 60.8 mg/mL/1.73 m2), whereas all 42 patients
(100%) who underwent gadolinium-enhanced DSA had
baseline chronic renal insufficiency (average pre-test SCr,
2.6 mg/dL; average creatinine clearance, 39.6 mg/mL/
1.73 m2). In 7 of 195 patients with chronic renal insuffi-
ciency, gadolinium-induced acute renal failure developed
after either MRA or DSA, for a combined incidence of
3.5%. In 3 patients (1.9%) renal failure developed after
intravenous infusion of gadolinium during MRA, and in 4
patients (9.5%) similar anuric complications developed af-
ter gadolinium-enhanced DSA. None of 65 patients with
normal creatinine clearance of greater than 80 mg/mL/
1.73 m2 had renal failure after gadolinium administration.
No other complications were related to performance of
the examinations in these patients. Average age of the 195
patients with baseline chronic renal insufficiency was 61
years (range, 20-92 years), whereas average age of patients
in whom acute renal failure developed was 71.5 years
(range, 52-92 years). Six patients with acute renal failure
were men, and one was a woman. None of the patients who
developed renal failure had a history of allergy to iodine-
based contrast agents or received other forms of contrast
material within 10 days before gadolinium infusion. No
patient with acute renal failure had begun angiotensin
converting enzyme (ACE) inhibition therapy within 30
days, or exhibited signs or symptoms of systemic infection,
clinical instability, or deviation from baseline renal function
before the period of observation. No patient had received
an organ transplant.
In the 7 patients with renal failure, average pre-test SCr
was 2.5 mg/dL, and baseline creatinine clearance before
receiving gadolinium was 32.5 mL/min 1.73 m2 (range,
9-61 mL/min/1.73 m2). This compares with average
baseline SCr of 2.2 mg/dL (P  .27) and average baseline
creatinine clearance of 38.2 1.6 mL/min/1.73 m2 (P
.33) in the 195 patients determined to have baseline pre-
test chronic renal insufficiency. Urinalysis in 7 patients with
oliguria showed granular cast formations in 4 patients and
low-grade proteinuria in 3 patients. Other risk factors
noted in the 7 patients with acute renal failure included
hypertension (71%), diabetes (57%), and known renal ar-
tery stenosis (29%) (Table). Five of 7 patients (71%) were
receiving long-term ACE inhibitor therapy; all stopped at
least 3 days before the examination).
Gadolinium-enhanced studies that resulted in acute
post-examination renal failure included DSA of the aorta (n
 2), DSA of lower extremity vasculature (n  2), and
MRA to display the infrarenal aorta and lower extremity
vessels (n  3). Indications for aortic DSA were diagnosis
and endovascular treatment of renal artery stenosis in 1
patient and evaluation of an iliac pseudoaneurysm in 1
patient. One MRA study was performed to evaluate a
pulsatile groin mass. The remaining DSA and MRA studies
were performed to evaluate lower extremity ischemia (Ta-
ble). All patients received undiluted triple-dose gadopentetate
dimeglumine (dihydrogen[N,N-bis[2-bis(carboxymethyl)-
amino]ethyl]-glycinate(5-)] gadolinate (2-). Average gad-
olinium dose administered in the 195 patients was 45 mL
(0.28 mmol/kg). In 5 of 7 patients with acute renal failure
the total dose did not exceed 0.4 mmol/kg. Two patients
received total doses of 0.41 and 0.42 mmol/kg, respec-
tively. The highest gadolinium dose was administered dur-
Table 1. Characteristic of patients with gadolinium-induced nephrotoxicity
Patient Age (y) Sex HTN Diabetes Test Indication
Gadolinium dose
Creatinine clearance
(mL/min/1.73 m2)
Dialysis
requiredmL mmol/kg
1 52 M No No DSA-Aorta Renal failure 60 0.42 29 Yes
2 53 M Yes Yes DSA-LE Ischemia 110 0.39 61 No
3 82 F Yes Yes MRA Groin mass 40 0.39 9 No
4 70 M No No MRA LE ischemia 60 0.41 17 Yes
5 86 M Yes No DSA-Aorta Iliac
pseudoaneurysm
40 0.27 15 Yes
6 92 M Yes Yes DSA-LE LE ischemia 60 0.34 41 No
7 66 M Yes Yes MRA LE ischemia 60 0.31 56 No
HTN, Hypertension; DSA, digital subtraction angiography; MRA, magnetic resonance angiography; LE, lower extremity.
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ing DSA and renal artery stenting procedure to treat renal
artery stenosis and ischemic nephropathy. SCr in all 7
patients were noted on each inpatient day, and is presented
as an average value (Fig 1). Each patient’s baseline pre-
MRA SCr served as a control value. Four patients had
oliguria and 3 patients had anuria during the observation
period (Fig 2). SCr peaked 3 days (range, 2-5 days) after
gadolinium infusion, and returned to baseline on day 7
(range, 4-12 days). Three patients temporarily required
inpatient hemodialysis. In these 3 patients SCr peaked at 4
days (range, 4-5 days) and baseline renal function was
regained after 10 days (range, 9-12 days). In the 4 patients
who did not receive dialysis SCr peaked after 3 days (range,
2-4 days), and values returned to baseline on day 6 (range,
4-8 days). Three patients (43%) subsequently underwent
arterial reconstruction surgery during the index admission;
the remaining patients were discharged as soon as renal
function recovered. Average hospital stay was 13.2 days
(range, 7-27 days). One patient died in the hospital, of
exacerbated congestive heart failure. Two patients, one
who required acute temporary dialysis and one who did
not, ultimately required long-term hemodialysis because of
deterioration in renal function.
DISCUSSION
Renal insufficiency combined with comorbid condi-
tions in patients with peripheral vascular disease increases
the incidence of contrast-induced renal failure after angiog-
raphy. In a study by Berns,8 3.6% of patients with baseline
pre-procedure SCr less than 2.0 mg/dL had iodinated
contrast–induced nephrotoxicity. This incidence increases
to 47% when SCr is 2.0 to 4.0 mg/dL, and climbs to more
than 80% with SCr greater than 4.0 mg/dL.8 Iodinated
contrast–induced renal failure may require temporary dial-
ysis in as many as 25% of affected patients. This increases the
length of stay, cost, and complexity of a given hospitaliza-
tion, and increases inpatient mortality.9 Three mechanisms
are purported to cause contrast-induced nephrotoxicity
from iodinated contrast media. Macrocirculatory and mi-
crocirculatory vasoconstriction occurs in response to radio-
contrast dye. In addition, direct tubular toxicity and pre-
cipitation of dye crystals within the renal tubules occur.
Prophylactic measures to prevent contrast-induced ne-
phropathy include pre-test intravenous hydration, acetyl-
cystine administration, and, most recently, dopamine re-
ceptor stimulation. In patients at high-risk, periprocedural
hydration to maintain urine output greater than 150
mL/hr resulted in a near 25% reduction in rate of contrast-
induced nephropathy in one review.10 Acetylcystine, a
thiol-containing compound, administered at a dose of 600
mg twice daily for 2 days before the procedure, on the day
of the procedure, and 1 day post-procedure likely guards
against contrast-induced nephropathy, because of its anti-
oxidant effects.11 Although in current use, larger confirma-
tory clinical trials are warranted. The latest strategy to
prevent contrast-induced nephropathy involves maintain-
ing glomerular filtration via selective activation of renal
dopamine A1 receptors. Dopamine A1 agonism results in
increased renal blood flow, primarily in the inner renal
cortex and medulla, which are the areas most susceptible to
contrast-induced toxicity.12 Randomized trials using this
new prophylactic agent are ongoing.
Gadolinium-based preparations have been developed
for use as substitutes for iodinated contrast medium. One
perceived advantage is that gadolinium-based contrast
agents are thought to have negligible nephrotoxicity. These
agents are most commonly used intravenously to reduce
proton relaxation time and improve image quality at MRA.
They have also been injected intra-arterially as a substitute
for iodinated contrast medium during DSA. We describe 7
patients, all with preinfusion renal insufficiency, in whom
acute oliguric and anuric renal failure developed after gad-
olinium infusion.
Gadolinium is a paramagnetic metallic element most
often used in contrast medium preparations for magnetic
resonance imaging (MRI). The contrast-enhancing effect
of the agent used in this series is brought about by the
di-N-methylglucamine salt of gadopentetate, the gadolin-
ium complex of diethylene-triamine-pentaacetic acid (Gd-
DTPA). During T1-weighted imaging, gadolinium short-
ens the spin-lattice relaxation time of the excited nuclei,
resulting in enhanced signal intensity on MRI.13 The addi-
tion of gadolinium-based contrast agents reduces MRA
time dramatically and can improve image quality compared
with older non-contrast-enhanced time-of-flight tech-
niques (Figs 3 and 4).
Similar to other radiocontrast agents, gadolinium may
result in nephrotoxicity as a result of the combined effects
of direct cellular toxicity and by increasing the concentra-
tion of urine. The normal medullary system is hypoxic
(10-20 mm Hg) and thus is susceptible to injury when
further hypoxic-inducing insults are present. The cellular
oxidant stress conditions resulting from contrast filtration
induce cellular ischemia and result in injury to the outer
medullary thick ascending limb of the renal tubule. Gado-
linium is thought to have much less toxic renal tubular
effects compared with iodinated agents, despite their simi-
lar behavior and excretory profiles. The pharmacokinetics
Fig 1. Baseline (black columns) and peak serum creatinine concen-
tration (gray columns) in 7 patients with gadolinium-induced
nephrotoxicity.
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of the gadolinium preparation used in our series, gado-
pentetate dimeglumine, is similar to that of iodinated con-
trast agents. After administration, the compound is distrib-
uted rapidly in the extracellular space, and is eliminated,
unchanged, by glomerular filtration in a dose-independent
fashion. Gadolinium ions form a stable complex with
DTPA that is intensely hydrophilic. Gadopentetate behaves
like biologically inert compounds such as mannitol or inu-
lin, with no noteworthy protein binding or inhibitory in-
teraction with enzymes. For doses up to 0.25 mmol of
gadopentetate per kilogram the plasma half-life is 90 min-
utes, corresponding to renal filtration rate. Renal clearance
is approximately 120 mL/min/1.73 m2 and is comparable
Fig 2. Serum creatinine concentration (circles) and urine output (squares) throughout observation period in 7
patients. Data represent mean  SEM.
Fig 3. Magnetic resonance angiogram with gadolinium contrast
enhancement shows pseudoaneurysm of the right profunda femo-
ris artery.
Fig 4. Digital subtraction angiogram with gadolinium contrast
enhancement shows a stenotic renal artery.
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to that for substances that are completely filtered, such as
inulin or chromium 51–ethylenediamine tetraacetic acid
(51Cr-EDTA).14 At 0.1 mmol/kg there is complete elimi-
nation via the kidneys, even in the presence of impaired
renal function (creatinine clearance,20 mL/min).14 The
plasma half-life has been reported to increase in relation to
degree of renal insufficiency, without an increase in extra-
renal elimination. The half-life increases to 30 hours in
these patients, yet there is no toxic degeneration of the
gadolinium chelate.15
Increasingly, MRA is supplanting angiography for pre-
operative vascular evaluation. MRA is accurate and reliable
for visualizing inflow and runoff vessels and for establish-
ment of stenotic grade if disease is present.16 Gadolinium
enhancement has resulted in greater image accuracy and
has helped expand the uses of MRA. It is particularly useful
in areas of high flow, such as the aortic arch and in renal and
visceral vessels, in which turbulence and motion may re-
duce the accuracy of conventional time-of-flight MRA.
BecauseMRA can be performed on an outpatient basis, it is
more cost-effective than contrast-enhanced angiography.17
Once proper sequences are programmed into the magnetic
resonance equipment software, the primary limitation is the
experience of the interpreting surgical team. When assessed
appropriately, the information derived from MRA is
equally, if not more, sensitive as conventional arteriogra-
phy.18,19
Gadolinium can be used during conventional arteriog-
raphy in patients with renal insufficiency. It has been used
instead of diluted iodinated contrast medium in patients
with predisposing risk factors for nephropathy because it
has a higher K-edge, which permits imaging with a higher
range of kilovoltage compared with that typically used for
iodine-enhanced imaging.20 This is particularly advanta-
geous during abdominal aortic imaging in large patients,
because the use of gadolinium (versus diluted iodine) cir-
cumvents the need to raise the kilovoltage during angiog-
raphy, which is known to compromise image quality. Intra-
arterial gadolinium infusion performs best during selective
angiography in small to medium vessels. Aortic evaluation
solely with intra-arterial gadolinium is less effective than
with full-strength iodinated contrast medium, because of
the large volume of gadolinium required and the high flow
rate in the aorta. Gadolinium is useful, however, for selec-
tively visualizing specific major aortic branches, such as the
celiac, mesenteric, or renal arteries. It is also useful for
endovascular procedures in which multiple, repeated selec-
tive angiographic views may be required.
Another advantage of gadolinium, in addition to de-
creased risk for nephropathy, is the low incidence of allergic
reactions.21 One disadvantage, however, is its cost, which is
approximately five times that of iodinated agents.
At present only three contrast agents have been ap-
proved by the US Food and Drug Administration for
intravenous administration during MRI: Gd-DTPA (Mag-
nevist; Berlex Laboratories, Wayne, NJ), Gd-DTPA-BMA
(Omniscan; Sanofi-Winthrop, New York, NY), and Gd-
HP-DO3A (Prohance; Bracco Diagnostics, Princeton,
NJ). When given at a typical dose of 0.1 mmol/kg for
general MRI, these agents demonstrate equivalent lesion
enhancement. Several studies have confirmed the safety of
intravenous gadolinium during MRA at doses up to 0.3
mmol/kg, even in patients with renal insufficiency. Con-
trast medium is most commonly administered in doses of
0.2 to 0.3 mmol/kg for most MRA studies. Carotid MRA
is typically performed with a dose of 0.1 mmol/kg. Use of
intra-arterial gadolinium has not been thoroughly exam-
ined to date, either in animals or in human beings, despite
prevalent off-label use. Before this report, the two pub-
lished cases of gadolinium-induced renal failure occurred
after arterial infusions during arteriography.5,6 From this,
the recommendation to limit intra-arterial doses to the
maximum range of 0.3 to 0.4 mmol/kg was adopted. If
intra-arterial gadolinium were considered, we would agree
with that recommendation. In this review, anuria requiring
hemodialysis developed in 2 patients who received intra-
arterial doses of 0.4 mmol/kg or greater. The incidence of
renal failure was higher in those receiving intra-arterial
gadolinium infusion (9.5% vs 1.9%). Quite possibly this
may be the result of a higher concentration of gadolinium
in the renal parenchyma, as opposed to that with intrave-
nous infusion. One factor that also must be considered is
microembolic showering to the renal circulation as a result
of suprarenal aortic injection of contrast medium. Despite
this, based on the limited number in this review, our data
do not prove that intra-arterial infusion is more problem-
atic than intra-venous administration of gadolinium. To
our knowledge, this is the first report to demonstrate renal
failure with doses less than 0.4 mmol/kg, regardless of
route, with one patient requiring hemodialysis.
The development of contrast-induced nephropathy is
related to the number of risk factors present, with the three
most important being renal insufficiency, diabetes mellitus,
and volume of contrast agent used. Other risk factors
include patient dehydration, advanced age, use of concom-
itant nephrotoxic drugs, multiple myeloma, heart failure,
and liver disease. These risk factors were identified from
experience with iodinated contrast agents, but they are
likely the same for patients who receive gadolinium-based
agents. All patients in this series had renal insufficiency, 2
had renal artery stenosis, and 5 of 7 had diabetes.
It is important to identify risk factors for iodinated or
gadolinium-based contrast-induced nephropathy to insti-
tute prophylactic measures to reduce the incidence of acute
renal failure in this high-risk population. We recommend
that the dose not exceed 0.3 mmol/kg, when possible, and
that 0.4 mmol/kg be considered the absolute limit.
Our study is limited primarily by its retrospective nature
and lack of a control group. It is, however, the first to
attempt to quantify the incidence of an event reported only
twice previously. Since we limited our evaluation to in-
patients receiving high doses of gadolinium, it is almost
certain that we have overestimated the true overall inci-
dence of gadolinium-induced renal failure because of selec-
tion bias. By limiting this study to in-patients, however, we
are confident that we did not miss patients who may have
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experienced renal toxicity unknowingly. As a corollary,
patients with known renal insufficiency who receive gado-
linium on an outpatient basis may need to be monitored
after discharge.
Acute anuric renal failure can occur after use of gado-
linium-based contrast agents in patients with underlying
renal insufficiency. Although the incidence is much lower
than with iodinated agents, patients at high risk must be
identified before infusion, and appropriate prophylactic
measures should be taken to reduce the incidence of con-
trast-induced nephropathy. Doses greater than 0.4
mmol/kg certainly should not be used, although our series
reveals that nephrotoxic effects may occur with a dose of
0.27 mmol/kg. Despite this, gadolinium-based contrast
agents appear to be approximately 20 times safer than
iodinated agents in patients with renal compromise.
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